ACSVL4 Activators
The regulation of acyl-CoA synthetase VL4 (ACSVL4) involves a network of chemical modulators that intricately influence its activity, connecting cellular lipid metabolism to essential signaling pathways. While direct activators specifically targeting ACSVL4 are not yet identified, the indirect modulation through interconnected metabolic and signaling pathways reveals a complex tapestry of regulatory mechanisms. One avenue through which ACSVL4 may be activated involves the inhibition of acyl-CoA synthetase VL3 (ACSVL3), as exemplified by A922500 and PF-06424439. By selectively inhibiting ACSVL3, these compounds indirectly influence ACSVL4 through shared metabolic pathways, altering fatty acid metabolism and potentially activating ACSVL4 as a downstream consequence of perturbed lipid signaling. The impact of long-chain acyl-CoA synthetase inhibitors, such as Triacsin C and SB-204990, on lipid metabolism indirectly affects ACSVL4 by altering the availability of specific fatty acids. This modulation can potentially activate ACSVL4, as changes in cellular lipid composition and signaling pathways associated with lipid metabolism play a crucial role in regulating its functions.
Compounds like Thiazovivin and T863, which target Rho-associated protein kinase (ROCK) and the fatty acid transporter CD36, respectively, showcase indirect modulation of ACSVL4 through the RhoA/ROCK signaling pathway or disruptions in fatty acid uptake. These compounds can potentially activate ACSVL4 by influencing actin cytoskeleton dynamics and fatty acid availability, respectively. Inhibition of acetyl-CoA carboxylase by TOFA and the selective inhibition of glutaminase by CB-839 indirectly impact ACSVL4 through alterations in fatty acid synthesis and glutamine metabolism, respectively. These compounds potentially activate ACSVL4 by influencing the availability of metabolites crucial for lipid synthesis and associated signaling pathways. Epigenetic modulators, such as 5'-Aza-2'-deoxycytidine, can influence ACSVL4 indirectly by altering DNA methylation and impacting the expression of genes associated with lipid metabolism. This epigenetic regulation can potentially activate ACSVL4 by modulating the transcriptional control of lipid-related pathways. In summary, the intricate network of ACSVL4 activators involves compounds that indirectly influence its activity through interconnected metabolic and signaling pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A 922500 | 959122-11-3 | sc-203793 | 10 mg | $270.00 | 2 | |
A922500 is a potent and selective inhibitor of acyl-CoA synthetase VL3 (ACSVL3). Its indirect impact on ACSVL4 stems from the shared metabolic pathways with ACSVL3, affecting fatty acid metabolism and potentially activating ACSVL4 in response to altered lipid signaling. | ||||||
Triacsin C Solution in DMSO | 76896-80-5 | sc-200574 sc-200574A | 100 µg 1 mg | $187.00 $843.00 | 14 | |
Triacsin C inhibits long-chain acyl-CoA synthetases, impacting lipid metabolism. Its indirect effects on ACSVL4 involve altering the availability of specific fatty acids, potentially activating ACSVL4 by influencing the cellular lipid composition and associated signaling pathways. | ||||||
TOFA (5-(Tetradecyloxy)-2-furoic acid) | 54857-86-2 | sc-200653 sc-200653A | 10 mg 50 mg | $97.00 $374.00 | 15 | |
TOFA inhibits acetyl-CoA carboxylase, impacting lipid metabolism. Its indirect modulation of ACSVL4 involves alterations in fatty acid synthesis, potentially activating ACSVL4 by influencing the cellular pool of fatty acids and associated lipid signaling pathways essential for its functions. | ||||||
CB 839 | 1439399-58-2 | sc-507354 | 10 mg | $140.00 | ||
CB-839 is a potent and selective inhibitor of glutaminase. Indirectly, it can impact ACSVL4 through altered glutamine metabolism, potentially activating ACSVL4 by influencing the availability of metabolites involved in lipid synthesis and associated signaling pathways. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
5'-Aza-2'-deoxycytidine is a DNA methyltransferase inhibitor. Its indirect effects on ACSVL4 involve epigenetic modifications that can influence the expression of genes associated with lipid metabolism, potentially activating ACSVL4 by modulating the transcriptional regulation of lipid-related pathways. | ||||||
(+)-Etomoxir sodium salt | 828934-41-4 | sc-215009 sc-215009A | 5 mg 25 mg | $151.00 $506.00 | 3 | |
Etomoxir is a selective inhibitor of carnitine palmitoyltransferase 1 (CPT-1). Its indirect impact on ACSVL4 involves alterations in fatty acid oxidation, potentially activating ACSVL4 by influencing the availability of fatty acids for acyl-CoA synthesis and modulating lipid signaling pathways. | ||||||